GLP-1 receptor agonists, SGLT2 inhibitors, and genomics transform Type 2 Diabetes management (2015-2025)

Type 2 diabetes (T2D) is a complex metabolic disorder driven by insulin resistance, β-cell dysfunction, and intricate genetic factors, posing a substantial global health challenge. Traditional treatments often struggle to address the multifactorial nature of the disease and its associated cardiovascular and renal complications. A deeper understanding of its molecular pathogenesis and the development of targeted therapies are crucial to improve long-term patient outcomes and move towards more personalized and effective interventions. This review highlights the critical advancements made in the last decade.

This comprehensive review systematically synthesized molecular, genetic, and pharmacological progress in Type 2 diabetes from 2015 to 2025. Researchers analyzed a decade of literature to identify key advancements in understanding T2D pathogenesis, diagnostics, and therapeutics. The review aimed to highlight the clinical translation of these findings and pinpoint critical priorities for future research, covering areas from genetic risk loci to novel drug classes and prevention strategies.

Over the past decade, significant strides have been made in T2D research. Large-scale GWAS and functional genomics have clarified numerous genetic risk loci and epigenetic mechanisms influencing disease susceptibility. Novel biomarkers, including circulating microRNAs and metabolomic signatures, have emerged, offering promising avenues for earlier detection and improved risk stratification. Therapeutically, incretin-based drugs, particularly GLP-1 receptor agonists and dual agonists (e.g., tirzepatide), alongside SGLT2 inhibitors, have revolutionized treatment. These agents not only provide superior glycemic control but also offer substantial cardiovascular-renal protection, fundamentally transforming patient outcomes. > These pharmacological advancements have shifted the paradigm of T2D management from merely glycemic control to comprehensive cardiometabolic risk reduction. Insights from these studies have also informed prevention strategies, emphasizing the critical roles of weight reduction, microbiome modulation, and precision interventions tailored to individual genetic risk profiles.